Search

Displaying results 581 - 590 of 10000 in total
  1. Drug

    Tolterodine

    go.drugbank.com/drugs/DB01036
    ApprovedInvestigational

    Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. Tolterodine acts on M2 and M3 subtypes of muscarinic receptors.

    Products: Mylan-tolterodine ER
  2. Drug

    Lisinopril

    go.drugbank.com/drugs/DB00722
    ApprovedInvestigational

    [A184844] Lisinopril was granted FDA approval on 29 December 1987.[L8384] … Lisinopril is an angiotensin converting enzyme inhibitor (ACEI) used to treat hypertension, heart failure, and myocardial infarction.

    Mixtures: LISINOPRIL IDROCLOROTIAZIDE EG, LISINOPRIL IDROCLOROTIAZIDE EGCategories: Agents Acting on the Renin-Angiotensin System, Compounds used in a research, industrial, or household setting
  3. Drug

    Bremelanotide

    go.drugbank.com/drugs/DB11653
    Approved

    [A179683] Since then it was investigated for its place in treating sexual dysfunction in men and women but is now only indicated for women. … [L9635] Bremelanotide was first described in the literature in 2003 when it was known by the investigational code PT-141.

  4. Drug

    Bisoprolol

    go.drugbank.com/drugs/DB00612
    ApprovedInvestigational

    It may be used alone or in combination with other drugs to manage hypertension[L7219] and can be useful in patients with chronic obstructive pulmonary disease (COPD) due to its receptor selectivity. … [A180472] Bisoprolol is generally well tolerated, likely due to its β1-adrenergic receptor selectivity and is a useful alternative to non-selective β-blocker drugs in the treatment of hypertension such

    Mixtures: BISOPROLOLO E IDROCLOROTIAZIDE AUROBINDO, BISOPROLOLO E IDROCLOROTIAZIDE AUROBINDOProducts: BISOPROLOLO EG, BISOPROLOLO EG STADA
  5. Drug

    Clindamycin

    go.drugbank.com/drugs/DB01190
    ApprovedInvestigationalVet approved

    The name lincomycin is derived from Lincoln, Nebraska, where it was first isolated from _Streptomyces lincolnensis_ found in a soil sample.[A190621] … [A190621] Interestingly, clindamycin appears to carry some activity against protozoans, and has been used off-label in the treatment of toxoplasmosis, malaria, and babesiosis.

    Products: CLINDAMCINA INFUSION 600 MG EN DEXTROSA AL 5 % POR 100 ML, Clindamycin in 5 Percent Dextrose
  6. Drug

    Eslicarbazepine acetate

    go.drugbank.com/drugs/DB09119
    ApprovedInvestigational

    Eslicarbazepine acetate (ESL) is an anticonvulsant medication approved for use in Europe, the United States and Canada as an adjunctive therapy for partial-onset seizures that are not adequately controlled … Eslicarbazepine acetate is marketed as Aptiom in North America and Zebinix or Exalief in Europe. It is available in 200, 400, 600, or 800mg tablets that are taken once daily, with or without food.

  7. Drug

    Mepivacaine

    go.drugbank.com/drugs/DB00961
    ApprovedInvestigationalVet approved

    Mepivacaine is effective topically only in large doses and therefore should not be used by this route. (From AMA Drug Evaluations, 1994, p168)

    Mixtures: MEPISEAL-ESynonyms: N-(2,6-Dimethylphenyl)-1-methyl-2-piperidinecarboxamide, N-(2,6-Dimethylphenyl)-1-methylpiperidine-2-carboxamide
  8. Drug

    Atenolol

    go.drugbank.com/drugs/DB00335
    ApprovedInvestigational

    Atenolol itself was developed early on in this history by Alvogen Malta under the trade name Tenormin and received FDA approval in September, 1981. … [A235860,A235865] A meta-analysis of over 145,000 patients showed the risk of stroke in patients taking atenolol may depend on the age of the patient.

    Mixtures: ATENOLOLO CLORTALIDONE EG, ATENOLOLO CLORTALIDONE EGProducts: ATENOLOLO EG
  9. Drug

    Rivaroxaban

    go.drugbank.com/drugs/DB06228
    ApprovedInvestigational

    FDA approved on July 1, 2011. … Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary.

    Products: RIVAROXABAN EG, RIVAROXABAN EG STADA
  10. Drug

    Ranibizumab

    go.drugbank.com/drugs/DB01270
    ApprovedInvestigational

    In order to improve drug delivery to the target organ, ranibizumab is available for intravitreal use. … [A246399] Ranibizumab was initially approved by the FDA in 2006 [A2301] and by the European Commission (EC) in 2007.[L41429] It is marketed under the brand names LUCENTIS and SUSVIMO.

    Products: LUCENTIS 10 MG/ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE, LUCENTIS SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 1.65mg/0.165ml